RN7SL505P

Across TCGA pan-cancer cohorts, RN7SL505P RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RN7SL505P’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where RN7SL505P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL505P is over-expressed in tumor.

STAD, LUSC, and PRAD are the cancer types where RN7SL505P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RN7SL505P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	II,III,IV	+0.383	<.001	6	view →
LUSC	Male	II,III,IV	+0.195	<.001	3	view →
PRAD	All	All	+0.086	.049	2	view →
ESCA	Male	All	+0.484	.024	1	view →
LUAD	All	All	+0.238	.036	1	view →
LIHC	All	All	+0.019	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RN7SL505P–STAD

Open the STAD breakdown →